{"filing":{"accession_number":"0001104659-26-092999","cik":"0000075252","ticker":"ACH","company_name":"ACCENDRA HEALTH INC/VA/","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2622667d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/75252/000110465926092999/tm2622667d2_8k.htm"},"events":[{"id":26315,"run_id":23908,"accession_number":"0001104659-26-092999","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Accendra Health issued a press release and earnings presentation reporting Q2 2026 financial results for the second quarter and six months ended June 30, 2026, including net revenue of $613.2M, operating losses, adjusted EBITDA, free cash flow, and updated 2026 full-year guidance of $2.45B–$2.55B in revenue and $300M–$320M in adjusted EBITDA.","company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27396,"accession_number":"0001104659-26-092999","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 2.02 disclosure is a press release reporting Accendra Health's financial results for Q2 2026 and six months ended June 30, 2026, including net revenue, operating losses, adjusted EBITDA, free cash flow, and updated 2026 guidance. The filing explicitly states the Company \"issued a press release regarding its financial results for the second quarter and six months ended June 30, 2026\" and furnishes it as Exhibit 99.1, which is the standard form for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:51:44.542777+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27397,"accession_number":"0001104659-26-092999","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure furnishes an earnings presentation for Q2 2026 financial results, which includes detailed financial statements, revenue of $613.2M, operating losses, and updated 2026 guidance ($2.45B-$2.55B revenue, $300M-$320M adjusted EBITDA). While the section also mentions CEO Edward Pesicka's intention to retire by end of 2026, the primary focus and substance of the disclosure is the quarterly earnings release with comprehensive financial results and forward guidance, making this an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:51:44.542777+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27396,"accession_number":"0001104659-26-092999","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 2.02 disclosure is a press release reporting Accendra Health's financial results for Q2 2026 and six months ended June 30, 2026, including net revenue, operating losses, adjusted EBITDA, free cash flow, and updated 2026 guidance. The filing explicitly states the Company \"issued a press release regarding its financial results for the second quarter and six months ended June 30, 2026\" and furnishes it as Exhibit 99.1, which is the standard form for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:51:44.542777+00:00","company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","filing_date":"2026-08-10"},{"id":27397,"accession_number":"0001104659-26-092999","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure furnishes an earnings presentation for Q2 2026 financial results, which includes detailed financial statements, revenue of $613.2M, operating losses, and updated 2026 guidance ($2.45B-$2.55B revenue, $300M-$320M adjusted EBITDA). While the section also mentions CEO Edward Pesicka's intention to retire by end of 2026, the primary focus and substance of the disclosure is the quarterly earnings release with comprehensive financial results and forward guidance, making this an earnings_release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:51:44.542777+00:00","company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","filing_date":"2026-08-10"}]}